Deliver Your News to the World

CSC’s DVC Wins $32.3 Million NIAID Contract to Establish Phase 1 Clinical Trial Unit


Quintiles Transnational Teams to Provide Clinical Research and Support

FALLS CHURCH, Va.- CSC (NYSE: CSC) announced today that DynPort Vaccine Company LLC (DVC), a CSC company, has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to establish and operate a Phase 1 clinical trial unit for infectious disease therapeutics.

The contract is valued at approximately $32.3 million over a seven-year period. DVC is teaming with Quintiles Transnational Corp. to complete this work.

Under the terms of the agreement, DVC and Quintiles will manage a Phase 1 clinical trial unit to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties of up to four new investigational products per year. As the prime contractor, DVC will provide overall project management, clinical operations management, quality assurance and co-development of protocols. Quintiles will provide Phase 1 clinical research and support services for the implementation and conduct of approved Phase 1 clinical trial protocols.

Trials will include therapeutic candidates for a broad range of infectious diseases. Investigational products tested could include measures to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.

“DVC and Quintiles have an established history of success—both individually and as partners—in clinical trial management of medical countermeasures,” said Dr. Robert V. House, president of DVC. “DVC has successfully advanced eight products into clinical trials in the last 10 years. This represents an expansion of DVC’s capabilities in pharmaceutical product development.”

“Quintiles is pleased to expand our existing government contracting relationship with DVC,” said Oren Cohen, M.D., senior vice president and managing director of Quintiles’ Public Health and Government Services business. “Quintiles’ portion of the work on this contract will take place in our new, state-of-the-art, 150-bed Phase 1 clinical research unit in Overland Park, Kan. The facility was dedicated in May 2007 and provides an ideal setting to perform multiple, concurrent clinical trials.”

Work will be performed by DVC at its headquarters in Frederick, Md.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.